Skip to main content
. Author manuscript; available in PMC: 2013 Apr 3.
Published in final edited form as: Nat Med. 2008 Nov 16;14(12):1325–1332. doi: 10.1038/nm.1883

Fig. 4.

Fig. 4

Src40-49Tat reverses CFA-induced thermal and mechanical hypersensitivity. (a) CFA injection reduces ipsilateral paw withdrawal latency (PWL) to radiant heat 24 h following CFA. (b) The effect of Src40-49Tat (10 pmol g−1, i.v.) on CFA-induced thermal hypersensitivity in terms of percentage Maximal Possible Effect (MPE; see Methods) of PWL. Inset: immunoblot and histogram showing tyrosine phosphorylation of NR2B 24 h after CFA and effects of Src40-49Tat or sSrc40-49Tat on normalized p-NR2B band intensity. (c) Histogram illustrating effects Src40-49Tat (0.1, 1 or 10 pmol g−1, i.v.) or of sSrc40-49Tat (10 pmol g−1, i.v.) or saline (0) on CFA-induced changes in PWL, expressed as percentage MPE of PWL. (d) The effect of Src40-49Tat and sSrc40-49Tat (10pmol g−1 i.v.) on CFA-induced reduction of paw withdrawal threshold (PWT) to Von-Frey stimuli in the ipsilateral paw, 6 h following CFA. (*p<0.05, **p<0.01 vs. control; mean±s.e.m.; n=5–9).